Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.
Researchers mapped how leukemia cells resist newer drugs, informing development of next-generation treatments when current ones stop working.
Dual functional genomics screen reveals a broad, convergent landscape of asciminib resistance mutations in BCR::ABL1 across the kinase domain, identifying resistance mechanisms relevant to clinical management of CML after asciminib failure and informing the design of next-generation allosteric ABL1 inhibitors.
What the study was
- Study design
- functional_genomics
- Category
- hematologic_malignancies
- Maturity
- translational
- Journal
- Genome Medicine
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.